Filed Pursuant to Rule 433
Registration Statement No. 333-269823
Issuer Free Writing Prospectus dated March 23, 2023
Relating to Preliminary Prospectus dated March 22, 2023

Altamira Therapeutics Ltd.

Up to 5,714,286 Common Shares
Pre-Funded Warrants to Purchase up to 5,714,286 Common Shares
Common Warrants to Purchase up to 5,714,286 Common Shares

This free writing prospectus relates to the public offering of common shares of Altamira Therapeutics Ltd. (the "Company") and should be read together with the preliminary prospectus dated March 22, 2023 (the "Preliminary Prospectus") that was included in Amendment No. 5 to the Registration Statement on Form F-1 (File No. 333-269823), which can be accessed through the following web link:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1601936/000121390023022155/ea175596-f1a5_altamira.htm

The Company has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting ThinkEquity LLC at (212) 895-9355.


altamira
therapeutics
DELIVERING RNA – BEYOND THE LIVER
Investor Presentation

Forward-Looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the Company's operation as a development-stage company with limited operating history and a history of operating losses, its ability to timely and successfully reposition our Company around RNA therapeutics and to divest or partner its business in neurotology, rhinology and allergology, the market acceptance and resulting sales from Bentrio® in international markets, the Company's dependence on the success of AM-125, AM-401 and AM-411, which are still in preclinical or clinical development, may eventually prove to be unsuccessful, if its product candidates obtain regulatory approval, its product candidates being subject to expensive, ongoing obligations and continued regulatory overview, enacted and future legislation may increase the difficulty and cost for the Company to obtain marketing approval and commercialization, the Company's ability to obtain, maintain and protect its intellectual property rights and operate its business without infringing or otherwise violating the intellectual property rights of others and the chance that certain intangible assets related to the Company's product candidates will be impaired. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Registration Statement on Form F-1, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov . Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Offering Summary

ISSUER	**Altamira Therapeutics Ltd.**
Listing / Symbol	Nasdaq: CYTO Listing Warrants on Nasdaq: CYTOW
Securities Offered	One Common Share and One Warrant (or for purchasers who would beneficially own more than 4.99% (or, at the election of the purchaser, 9.99%) of the outstanding shares of common stock, one pre-funded warrant and one warrant)
Expected Offering Size	$8,000,000
Use of Proceeds	• Research & Development • Working Capital and General Corporate Purposes • Repay $1M Debt
Sole Book-Running Manager	ThinkEquity

Disruptive, Proprietary RNA Delivery Technology Platform



OligoPhore™ (siRNA) SemaPhore™ (mRNA) Platforms

- Proprietary 21 amino acid peptide for efficient delivery of RNA into target cells (nanoparticles)
- Non-hepatic targets, unlike mainstream technology
- Validated in 15 disease models so far
- Patented platform (2034+), building additional IP

RNA Market Taking Off

- Rapidly growing number of RNA therapeutics
- Active M&A, licensing environment
- Delivery platforms for partnering with pharma & biotech

Two Novel, Early-Stage Drug Candidates

- KRAS-driven cancers (AM-401) - IND expected in 2023
- Rheumatoid Arthritis (AM-411) - IND expected in 2024

Divesting / Partnering Legacy Assets

- Unlock intrinsic value of inner ear & OTC assets
- Extra, non-dilutive funding potential

How Our Technology Works

OligoPhore™ /SemaPhore™ are nanoparticles comprising a proprietary peptide + RNA payload designed to enable safe and effective delivery by systemic administration.



Stability	RNA complexed in nanoparticle format and only released inside of cells after uptake
Extrahepatic delivery	Not sequestered in liver, permeates inflamed pathological tissues (passive targeting)
Endosomal escape	Efficient release within target cell, substantially higher than current technology, observed in murine preclinical studies
Selectivity	Acts on targets in diseased tissues only
Safety	No cellular or adaptive immune responsivity to nanoparticle components or RNA after multiple serial doses, and no organ toxicities in mice

RNA Delivery is One of the Key Challenges

Exemplary listing of companies active in RNA therapeutics and delivery (list not exhaustive)

Silence gene expression	Promote protein expression	Deliver RNA therapeutic to target
• Short interfering RNA (siRNA) • Antisense oligonucleotides (ASOs)	• Messenger RNA (mRNA)	• Lipid nanoparticles • Virus-based vectors • Ligand conjugates • **Peptide-based nanoparticles**
Alnylam, arrowhead pharmaceuticals, AstraZeneca, IONIS, Lilly, Novartis, novo nordisk, ProQR Therapeutics, Sarepta Therapeutics, Silence Therapeutics, Silentis, Stoke Therapeutics	Arcturus Therapeutics, AstraZeneca, BioNTech, CureVac, Lilly, Merck, moderna, novo nordisk, Pfizer, sanofi, Translate Bio, ultragenyx	sirnaomics ($635 million), altamira therapeutics ($4.4 million), Arbutus Biopharma ($476 million), entrada Therapeutics ($357 million), Dicerna (a Novo Nordisk company) ($3.3 billion*), PepGen ($402 million)

*Represents valuation of the company derived from 2021 acquisition
Figures are sourced from S&P Capital IQ as of March 7, 2023

Disruptive Technology Growth Opportunities

frontiers

Frontiers in Bioengineering and Biotechnology, March 2021

The Limitless Future of RNA Therapeutics

Tulsi Ram Damase[1], Roman Sukhovershin[1], Christian Boada[2], Francesca Taraballi[2,3], Roderic I. Pettigrew[2] and John P. Cooke[1]

- High specificity
- Cost effective
- Relatively simple to manufacture
- Can target previously undruggable pathways
- Disruptive technology





STRONG GROWTH—STARTING IN 2018

ONLY THE BEGINNING!

*Research and Markets; Allied Market Research

AM-401: Stop the "Beating Heart" of Tumors

Knock down various KRAS mutations with *poly*KRAS^{mut} OligoPhore™ nanoparticles

to inhibit cell proliferation in KRAS driven colorectal, pancreatic, or non small cell lung cancer.

- Mutated KRAS may cause cancer to grow
- Found in 1/5 of all human cancers, particularly in:
  - Pancreatic cancer (85-90%)
  - Colorectal cancer (40%)
  - Non-small cell lung cancer (30-35%)
- 150,000 cases diagnosed in US p.a.
- ~1M deaths per year world-wide
- Considered "undruggable" for decades

*KPC pancreatic tumor model in mice; Strand et al., 2019

Many mutations known, G12D, G12V, and G12C accounting for >50%



OligoPhore™ *poly*KRAS^{mut} siRNA transfects tumor cells, not healthy or uninvolved cells





OligoPhore™ *poly*KRAS^{mut} significantly reduces pancreatic tumor volume growth

KPC pancreatic tumor model in mice; Strand et al., 2019

altamira therapeutics

AM-401

KRAS driven cancer
IND targeted for 2023

- High unmet medical need – most aggressive tumors
- Small molecule G12C inhibitors approved in NSCLC
  - Sotorasib (Lumakras, Amgen), Adagrasib (Krazati, Mirati)
- Multiple other small molecule inhibitors under development (G12C, G12D…), but few competing RNA projects (G12D or KRAS modulators)

AM-401 KEY DIFFERENTIATING FACTORS

- *poly*KRAS^{mut} allows to target different mutations and is thus **polyvalent**
- Blocking production of KRAS by degrading mRNA to cause **less resistance** than inhibition of KRAS
- Small molecule inhibitors have significant side effects, particularly when combined with other agents
  OligoPhore™ **targets specifically** tumor cells

AM-411: Block Inflammation in Rheumatoid Arthritis

Knock down NF-κB (p65),
key checkpoint in RA inflammation.

- Chronic autoimmune disease
- Causes joint swelling and pain
  - Reduced QoL and productivity
- Affects 1 out of 28 women / 59 men
- No cure available, but various treatment options:
  - Disease modifying anti-rheumatic drugs (DMARDs)
  - Non-steroidal anti-inflammatory drugs (NSAIDs)
  - Corticosteroids
- Major shortcomings of therapies:
  - Drug resistance (up to 50% of patients)
  - Systemic adverse reactions (e.g. rash, hair loss, altered liver function, low blood cell counts, nausea, weight loss, increased infections, and neuropathy)

OligoPhore™ p65 stabilizes ankle swelling and reduces arthritis score



OligoPhore™ p65 reduces inflammation and protects against bone erosion



Collagen-antibody induced arthritis model in mice, Zhou et al., 2014.

altamira therapeutics

AM-411

Rheumatoid arthritis
IND targeted for 2024

- High unmet medical need
- Global rheumatoid arthritis market - $57.9 Billion in 2019 → $62.9 Billion in 2027
  - Expiration of patents, biosimilars arriving
  - High hopes for novel Tx class of JAK inhibitors gave way to disappointment due to safety issues

AM-411 KEY DIFFERENTIATING FACTORS

Mediators of inflammation play many physiological roles in healthy tissues – AM-411 targets only inflamed tissues
Reduced systemic side effects

Blocking production of an NF-κB component by degrading mRNA to cause less resistance than inhibition of NF-κB
Less likelihood of resistance

Corporate Strategy

- **Leverage versatility of technology**
  - Demonstrated to work in multiple disease areas – successfully tested in 15 animal models
  - Suitable for siRNA, mRNA, ASOs, circular RNA
- **Particularly well suited** for indications in oncology and inflammatory disorders
- **Selecting two therapeutic indications** to showcase technology
  - KRAS driven cancers – AM-401
  - Rheumatoid arthritis – AM-411
  - Partner upon IND or Phase 1
- **Leverage technology platform** through out-licensing
  - Become drug delivery platform company

OligoPhore™ has been tested *in vivo*...

- Pancreatic and colorectal cancer (KRAS)
- Ovarian cancer (TAM: AXL)
- Lung cancer (ETV-2)
- Metastatic Melanoma (NF-κB)
- Adult T Cell Leukemia/Lymphoma (NF-κB)
- Sarcoma (MYCT-1)
- Necrotizing enterocolitis (NF-κB)
- Rheumatoid and osteoarthritis (NF-κB)
- Atherosclerosis (JNK2)
- Metabolic syndrome/Obesity (ASXL2)
- Aortic Aneurysm (NF-κB)
- Osteoarthritis (NF-κB)

SemaPhore™ has been tested *in vivo*...

- Osteoarthritis (WNT16)
- Atherosclerosis (p27Kip1)
- Aortic Aneurysm (SOD2)

altamira therapeutics


United States Patent
Wickline et al.
Patent No.: US 9,987,371 B2
Date of Patent: Jan. 5, 2018

WORLDWIDE EXCLUSIVE LICENSE FROM WASHINGTON UNIVERSITY

Patent covering OligoPhore™ / SemaPhore™ platform

- Compositions comprising a peptide-polynucleotide complex
- Methods for delivering such nanoplexes
- Coverage until 2034 (+ potential extension)
- Generating further IP (filed e.g. *poly*KRAS^{mut} – potential coverage until 2043)
- Proprietary manufacturing process

Capitalization Overview

	Pro Forma Pre-Offering
Common Shares	2,387,987
Convertible Note Conversion Shares and/or Pre-Funded Warrants*	3,467,860
Warrants Issued Upon Convertible Note Conversion**	3,467,860
Warrants (WAEP: $57.60)	99,171
Options (WAEP: $20.84)	157,730
Fully Diluted Shares Outstanding	9,580,608



*Represents the conversion of approximately $4.8mm of a convertible loan into 890,261 shares of common stock and 2,577,600 pre-funded warrants based on an assumed offering price of $1.40 per share

**Number of Warrants is based on an assumed offering price of $1.40 per share. Exercise price will equal the exercise price of the warrants in the offering

Management Overview

Thomas Meyer, PhD

CEO & CHAIRMAN

- Company founder
- Funded and grew Company since 2003
- 14 years with Disetronic Group including CEO and BoD member (>20% sales CAGR, $3B market cap)

Covadonga Pañeda, PhD

CHIEF OPERATING OFFICER

- Joined as CDO in 2022
- 18 years experience in FDA/EMA drug development
- Non-clinical and clinical study design and regulatory submissions
- 7 years in RNAi for ophthalmology

Marcel Gremaud, CPA

CHIEF FINANCIAL OFFICER

- Working for Company since 2013
- ~30 years experience in controlling and accounting
- International pharma companies and start-ups

Samuel Wickline, MD

CHIEF SCIENTIFIC ADVISER

- Joined in 2021 through acquisition of Trasir Tx
- Prof. of Cardiovascular Sciences, Molecular Physiology and Pharmacology at USF
- Former Prof. of Med., Physics, Biomedical Engr, Cell Biology and Physiology at Wash U

Investor Summary – RNA Business

RNA technology coming of age

- Disruptive potential in human medicine
- Rapidly growing # of RNA therapeutics

Extensive proof of concept

- Successfully tested *in vivo* in 15 different disease models, 30+ papers published

Altamira has unique, versatile RNA delivery technology platform

- Patented, under license from Wash U
- Suitable for different types of RNA molecules

Showcase programs in oncology and rheumatoid arthritis

- First IND expected to be filed in 2023
- Technology platform out-licensing as business model

Addressing major challenges in RNA delivery

- Reaching extrahepatic targets
- Strong endosomal release

Potential divestiture/partnering of Legacy Assets

- Unlock intrinsic value
- Source of non-dilutive funding

altamira therapeutics

Thomas Meyer
CEO
thm@altamiratherapeutics.com

Covadonga Pañeda
COO
cop@altamiratherapeutics.com

www.altamiratherapeutics.com

Legacy Programs to be Divested / Partnered

Become focused
"Pure play" RNA delivery company

Monetize legacy assets
through divestiture, out-licensing

Bentrio®
Protection against airborne particles

- Drug-free, preservative-free formulation, applied as nasal spray
- Three clinical trials demonstrating safety and efficacy in allergic rhinitis
- OTC product
  - Commercialized in selected European and Asian countries (distributors)
  - FDA 510(k) clearance in June 2022
- Viral infection as additional indication
- Advanced discussions on North America, Europe and other key markets

AM-125
Treatment of acute vestibular syndrome (vertigo)

- Rx product, applied as nasal spray
- Reformulation of oral betahistine
  - Global market $450M (ex US) – standard of care for vertigo
  - Poor bioavailability
- Patent coverage up to 2038
- Proof of concept in Phase 2, preparing Phase 3 trial and IND
- Potential for use in other indications (e.g. Prader Willi, dementia…)

Press Release Issued and Subsequent Capital Raise

Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties

- Bentrio® remained detectable by fluorescence for up to 210 minutes in subjects' nasal passages vs. 60 minutes with saline nasal spray control
- Long nasal residence time supports extended protective effects against airborne allergens and other potentially harmful particles
- At-the-market financing completed March 3, 2023
- 989,068 shares sold at an average price of $3.54
- Total proceeds are $3,501,300.72